-- Days : -- HRS : -- MIN : -- SEC

Register Now →

Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|December 15, 2023

Teaser: Examining the Role of a Novel Class of Medications for the Management of Multiple Sclerosis

Episodes in this series

EP. 1 Teaser: Examining the Role of a Novel Class of Medications for the Management of Multiple Sclerosis

EP. 1 Teaser: Examining the Role of a Novel Class of Medications for the Management of Multiple Sclerosis

Video 1 - 3 KOLs are featured in, "Multiple Sclerosis: Impact, Types, Pathophysiology, and Progression"

EP. 2 Multiple Sclerosis: Impact, Types, Pathophysiology, and Progression

Video 2 - 3 KOLs are featured in, "Assessing Limitations, Costs, Mobility and Cognition in Progressive Multiple Sclerosis"

EP. 3 Assessing Limitations, Costs, Mobility and Cognition in Progressive Multiple Sclerosis

3 KOLs in this program

EP. 4 Examining Key Unmet Needs in Multiple Sclerosis

3 KOLs in this program

EP. 5 Patient Satisfaction: Opportunity for Better Multiple Sclerosis Therapies

A panel of 3 experts on multiple sclerosis

EP. 6 MS Treatment Guidelines: Expert Insights on Updates and Decision-Making

A panel of 3 experts on multiple sclerosis

EP. 7 Incorporating a Subcutaneous Novel Therapy into Multiple Sclerosis Treatment

A panel of 3 experts on multiple sclerosis

EP. 8 Examining Challenges with Drug Switching and Step Therapy in MS Treatment

A panel of 3 experts on multiple sclerosis

EP. 9 Typical Payer Coverage Criteria for Multiple Sclerosis Therapies

A panel of 3 experts on multiple sclerosis

EP. 10 BTK Inhibitors' Rationale and Potential Role in Multiple Sclerosis Treatment

A panel of 3 experts on multiple sclerosis

EP. 11 Updates in Recent Clinical Trials in the Treatment of Multiple Sclerosis

A panel of 3 experts on multiple sclerosis

EP. 12 Primary Progressive Multiple Sclerosis Treatment Landscape: Emerging Therapies

A panel of 3 experts on multiple sclerosis

EP. 13 Multiple Sclerosis: Looking Toward the Future

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Experts featured in this series.

The Right Fit First: How Psychiatrists Approach Initial Treatment and Patient Adherence

ByPatrick Runnels, MD, MBA,Ginger Shupe, MD,Gus Alva, MD, DFAPA,Joe Goldberg, MD

Published: June 23rd 2026 | Updated: June 16th 2026

Experts featured in this series.

Formulary Frustrations: How Insurance Constraints Shape Psychiatric Treatment Decisions

ByPatrick Runnels, MD, MBA,Ginger Shupe, MD,Gus Alva, MD, DFAPA,Joe Goldberg, MD

Published: June 23rd 2026 | Updated: June 16th 2026

Navigating the Human Side of Extrapulmonary Neuroendocrine Carcinoma: Patient Burden and Caregiver Support

ByRyan Haumschild, PharmD, MBA,William K. Oh, MD,Aman Chauhan, MD,Namrata Vijayvergia, MD,Sandy Kotiah, MD

June 22nd 2026

The 5-Year Horizon: Evolving Paradigms in Ischemic Stroke Management

ByMark Makhinson, PharmD, MBA,Andrew Russman, DO, FAHA, FAAN,Danison Emmerson, MD,David Z. Rose, MD

June 22nd 2026

Closing the Gap: Underrecognition and the Critical Need for Early Diagnosis in Extrapulmonary Neuroendocrine Carcinoma

ByRyan Haumschild, PharmD, MBA,William K. Oh, MD,Aman Chauhan, MD,Namrata Vijayvergia, MD,Sandy Kotiah, MD

June 22nd 2026

Trending on AJMC

CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes

ATTR-CM Incidence, Prevalence Rose Sharply in the US

Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC

First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention

FDA Approves Palbociclib for HR+, HER2+ Breast Cancer Maintenance